4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

September 6, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Mylan, brexit

It’s Friday, meaning the weekend is within reach and it’s time for a rundown of the most popular articles on …

Roche celebrates European approval of Tecentriq combo in first-line lung cancer

September 6, 2019
Medical Communications, Sales and Marketing Cancer, Europe, Roche, lung cancer, pharma, tecentriq

Roche has confirmed that its immunotherapy Tecentriq (atezolizumab) has been approved in Europe in combination with chemotherapy (carboplatin and etoposide) …

novartis_window

Novartis’ Lucentis secures European approval for infants with rare eye disease

September 6, 2019
Medical Communications, Sales and Marketing Europe, Lucentis, Novartis, eye disease, pharma

Novartis has made the surprise announcement that its VEGF inhibitor Lucentis (ranibizumab) has been awarded marketing authorisation from the European …

Experimental Novartis drug secures FDA Breathrough designation for rare lung cancer

September 6, 2019
Medical Communications, Sales and Marketing Cancer, Novartis, capmatinib, lung cancer, pharma

Novartis is celebrating the acceptance of its experimental cancer drug capmatinib by the FDA onto an accelerated review pathway, securing …

shutterstock_57369385

View of pharma industry sinks to new low in US, poll reveals

September 6, 2019
Medical Communications US, pharma

The public have always been reticent with their trust in the pharmaceutical industry, but that trust has hit an all-time …

shutterstock_273326141

Boehringer and Lupin team up to battle KRAS-driven cancers in $700m+ deal

September 5, 2019
Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, KRAS, Lupin, collaboration, pharma

Boehringer Ingelheim is set to join forces with Lupin after the pair sealed a partnership agreement to develop, license, and …

janssen_latest_logo_on_sign_closer

Janssen’s Stelara becomes first European-approved biologic IL-12/IL-23 inhibitor for ulcerative colitis

September 5, 2019
Sales and Marketing Europe, Janssen, Stelara, pharma, ulcerative colitis

Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug …

opdivo_1_1

BMS’ Opdivo falls short at Phase 3 in glioblastoma multiforme

September 5, 2019
Research and Development BMS, glioblastoma multiforme, opdivo, pharma

Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the …

shutterstock_3

Cancer drugs have surged since the 80s to account for 1 in 4 FDA approvals, report reveals

September 5, 2019
Research and Development, Sales and Marketing Cancer, FDA, US, pharma

The number of cancer drug approvals in the US has surged over the last decade to account for over one …

470px-blank_ireland

Ireland will not suffer immediate medicine shortages in event of no-deal Brexit, says health authority

September 5, 2019
Medical Communications, Sales and Marketing England, Ireland, UK, brexit, pharma

Though MPs are moving forward with their plan to block UK Prime Minister Boris Johnson’s supposed no-deal Brexit from the …

ai_graphic

Key legal considerations in accelerating pharma using artificial intelligence

September 4, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, artificial intelligence, pharma

Charlotte Walker-Osborn, Partner and International Technology Sector Head and Nabil Asaad, Senior Associate, Intellectual Property Law Group – both from …

w3_banners6

FREE WEBINAR: Leveraging technology for optimal engagement

September 4, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, Webinar, Within3, pharma

Join Pharmafocus and Within3 for a special webinar event on Thursday, 19 September, for a session exploring the changing trends …

merckwindow_web

Keytruda scores EU approval in combination with Inlyta for first-line advanced renal cell carcinoma

September 4, 2019
Research and Development, Sales and Marketing EU, Europe, MSD, keytruda, pharma, renal cell carcinoma

The European Commission has awarded yet another authorisation in the region to MSD’s Keytruda, this time in combination with the …

shutterstock_212432119

Ardelyx’s tenapanor combo meets all key goals at Phase 3 in hyperphosphatemia patients on dialysis

September 4, 2019
Research and Development Ardelyx, pharma, tenapanor

Ardelyx has revealed that its small molecule, non-binder, phosphate absorption inhibitor tenapanor met all primary and key secondary endpoints at …

NICE recommends Novartis’ gene therapy Luxturna for inherited retinal dystrophy

September 4, 2019
Research and Development, Sales and Marketing Luxturna, NHS, NICE, UK, gene therapy, pharma

NICE has chosen to recommend the use of Novartis’ one-time gene therapy Luxturna (voretigene neparvovec) for use on the NHS …

astrazeneca_plaque

AZ’s Tagrisso secures China approval in first-line advanced lung cancer

September 4, 2019
Research and Development, Sales and Marketing AstraZeneca, China, Tagrisso, lung cancer, pharma

AstraZeneca’s Tagrisso (osimertinib) has secured approval in China from the country’s National Medical Products Administration (NMPA) in the first-line treatment …

sandoz

Sandoz acquires global commercialisation rights to Polpharma’s multiple sclerosis biosimilar

September 3, 2019
Manufacturing and Production, Sales and Marketing Polpharma, Sandoz, biosimilar, multiple sclerosis, pharma

Sandoz has revealed that it has sealed a deal with Polpharma Biologics to commercialise the latter’s proposed biosimilar version of …

shutterstock_2

NICE issues new quality standard for cerebal palsy treatment

September 3, 2019
Manufacturing and Production, Research and Development

NICE has moved to publish a draft quality standard on the treatment of cerebral palsy (CP) in adults, it has …

novartis_outside_1

Novartis’ ofatumumab outclasses Sanofi’s Aubagio at Phase 3 in relapsing multiple sclerosis

September 3, 2019
Manufacturing and Production, Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, pharma

New data from two Phase 3 studies have indicated that Novartis’ ofatumumab outperformed Sanofi Genzyme’s Aubagio (teriflunomide) in the treatment …

astrazeneca_sign_sky

AstraZeneca shows off Farxiga heart failure efficacy at ESC 2019

September 3, 2019
Manufacturing and Production, Research and Development

AstraZeneca has revealed new Phase 3 data illustrating that Farxiga (dapagliflozin), in combination with standard of care, met its primary …

The Gateway to Local Adoption Series

Latest content